DT-Web

DB00315 - Zolmitriptan


Identification
Name Zolmitriptan
Accession Number DB00315 (APRD00376)
Type small molecule
Description Zolmitriptan is a synthetic tryptamine derivative and appears as a white powder that is readily soluble in water. [Wikipedia]
Structure
MOL SDF PDB SMILES InChI
Categories (*)
Molecular Weight 287.3568
Groups approved
Monoisotopic Weight 287.163376931
Pharmacology
Indication For the acute treatment of adult migraine with or without auras.
Mechanism of action Zolmitriptan binds with high affinity to human 5-HT1B and 5-HT1D receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
Absorption Mean absolute oral bioavailability is approximately 40%. Food has no affect on the rate and extent of absorption.
Protein binding 25%
Biotransformation Hepatic. There have been three metabolites identified: indole acetic acid, N -oxide, and N-desmethyl metabolites. However, the N-desmethyl is the only active metabolite.
Route of elimination Not Available
Toxicity Not Available
Affected organisms
  • Humans and other mammals
Interactions
Drug Interactions
Drug Mechanism of interaction
Almotriptan Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and almotriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Amitriptyline Use of two serotonin modulators, such as zolmitriptan and amitriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Amoxapine Use of two serotonin modulators, such as zolmitriptan and amoxapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Bromocriptine Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, bromocriptine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. Use of two serotonin modulators, such as zolmitriptan and bromocriptine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Buspirone Use of two serotonin modulators, such as zolmitriptan and buspirone, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Cabergoline Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, carbergoline, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. Use of two serotonin modulators, such as zolmitriptan and carbergoline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Citalopram The use of two serotonin modulators, such as zolmitriptan and citalopram, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Clomipramine Use of two serotonin modulators, such as zolmitriptan and clomipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
D-Tryptophan Use of two serotonin modulators, such as zolmitriptan and D-tryptophan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Desipramine Use of two serotonin modulators, such as zolmitriptan and desipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Desvenlafaxine Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
Dextromethorphan Use of two serotonin modulators, such as zolmitriptan and dextromethorphan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Dihydroergotamine Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, dihydroergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Doxepin Use of two serotonin modulators, such as zolmitriptan and doxepin, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Duloxetine Use of two serotonin modulators, such as zolmitriptan and duloxetine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Eletriptan Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and eletriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Ergoloid mesylate Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergoloid mesylate, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Ergonovine Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergonovine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Ergotamine Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, ergotamine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Escitalopram Use of two serotonin modulators, such as zolmitriptan and escitalopram, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Fluoxetine Use of two serotonin modulators, such as zolmitriptan and fluoxetine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Fluvoxamine Use of two serotonin modulators, such as zolmitriptan and fluvoxamine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Frovatriptan Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and frovatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Furazolidone The MAO inhibitor, furazolidine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing furazolidine are contraindicated.
Imipramine Use of two serotonin modulators, such as zolmitriptan and imipramine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Isocarboxazid The MAO inhibitor, isocarboxazid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing isocarboxazid are contraindicated.
L-Tryptophan Use of two serotonin modulators, such as zolmitriptan and L-tryptophan, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Linezolid The MAO inhibitor, linezolid, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing linezolid are contraindicated.
Lithium Use of two serotonin modulators, such as zolmitriptan and lithium, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Maprotiline Use of two serotonin modulators, such as zolmitriptan and maprotiline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Meperidine Use of two serotonin modulators, such as zolmitriptan and meperidine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Methylergonovine Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, methylergonovine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Methysergide Possible severe and prolonged vasoconstriction
Milnacipran Use of two serotonin modulators, such as zolmitriptan and milnacipran, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Mirtazapine Use of two serotonin modulators, such as zolmitriptan and mirtazapine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Moclobemide The MAO inhibitor, moclobemide, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing moclobemide are contraindicated.
Naratriptan Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and naratriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Nefazodone Use of two serotonin modulators, such as zolmitriptan and nafazodone, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Nortriptyline Use of two serotonin modulators, such as zolmitriptan and nortriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Paroxetine Use of two serotonin modulators, such as zolmitriptan and paroxetine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Pergolide Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, pergolide, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Phenelzine The MAO inhibitor, phenelzine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing phenelzine are contraindicated.
Procarbazine The MAO inhibitor, procarbazine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing procarbazine are contraindicated.
Promethazine Use of two serotonin modulators, such as zolmitriptan and promethazine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Protriptyline Use of two serotonin modulators, such as zolmitriptan and protriptyline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Rasagiline The MAO inhibitor, rasagiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing rasagiline are contraindicated.
Rizatriptan Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and rizatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
S-Adenosylmethionine Use of two serotonin modulators, such as zolmitriptan and S-adenosylmethionine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Selegiline The MAO inhibitor, selegiline, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing selegiline are contraindicated.
Sertraline Use of two serotonin modulators, such as zolmitriptan and sertraline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Sibutramine Use of sibutramine, which inhibits serotonin reuptake, and zolmitriptan, a serotonin 5-HT1D receptor agonist, may cause serotonin syndrome. Concomitant therapy is contraindicated.
St. John's Wort Use of two serotonin modulators, such as zolmitriptan and St. John's Wort, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Sumatriptan Concomitant use of two serotonin 5-HT1D receptor agonists, such as zolmitriptan and sumatriptan, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated.
Tapentadol Use of two serotonin modulators, such as zolmitriptan and tapentadol, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Tramadol The use of two serotonin modulators, such as zolmitriptan and tramadol, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Tranylcypromine The MAO inhibitor, tranylcypromine, may increase the serum concentration of zolmitriptan by decreasing its metabolism. Concomitant therapy and use of zolmitriptan within two weeks of discontinuing tranylcypromine are contraindicated.
Trazodone Use of two serotonin modulators, such as zolmitriptan and trazodone, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Trimipramine Use of two serotonin modulators, such as zolmitriptan and trimipramine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Venlafaxine Use of two serotonin modulators, such as zolmitriptan and venlafaxine, may increase the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
Food Interactions Not Available

Targets


5-hydroxytryptamine 1B receptor
Name 5-hydroxytryptamine 1B receptor
Gene Name HTR1B
Pharmacological action yes
Actions agonist
References
  • Le Grand B, Panissie A, Perez M, Pauwels PJ, John GW: Zolmitriptan stimulates a Ca(2+)-dependent K(+) current in C6 glioma cells stably expressing recombinant human 5-HT(1B) receptors. Eur J Pharmacol. 2000 Jun 2;397(2-3):297-302. - Pubmed
  • Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10. - Pubmed
  • de Almeida RM, Nikulina EM, Faccidomo S, Fish EW, Miczek KA: Zolmitriptan--a 5-HT1B/D agonist, alcohol, and aggression in mice. Psychopharmacology (Berl). 2001 Sep;157(2):131-41. - Pubmed
  • Reuter U, Salomone S, Ickenstein GW, Waeber C: Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia. 2004 May;24(5):398-407. - Pubmed
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
  • Whale R, Bhagwagar Z, Cowen PJ: Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors? Psychopharmacology (Berl). 1999 Jul;145(2):223-6. - Pubmed
  • Hargreaves RJ, Shepheard SL: Pathophysiology of migraine--new insights. Can J Neurol Sci. 1999 Nov;26 Suppl 3:S12-9. - Pubmed
  • Gowin JL, Swann AC, Moeller FG, Lane SD: Zolmitriptan and human aggression: interaction with alcohol. Psychopharmacology (Berl). 2010 Jul;210(4):521-31. Epub 2010 Apr 21. - Pubmed
  • Pascual J: [Mechanism of action of zolmitriptan] Neurologia. 1998 Oct;13 Suppl 2:9-15. - Pubmed
  • Martin GR: Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 Oct;17 Suppl 18:4-14. - Pubmed
DTHybrid score 0.4667
5-hydroxytryptamine 1D receptor
Name 5-hydroxytryptamine 1D receptor
Gene Name HTR1D
Pharmacological action yes
Actions agonist
References
  • Whale R, Bhagwagar Z, Cowen PJ: Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors? Psychopharmacology (Berl). 1999 Jul;145(2):223-6. - Pubmed
  • Hargreaves RJ, Shepheard SL: Pathophysiology of migraine--new insights. Can J Neurol Sci. 1999 Nov;26 Suppl 3:S12-9. - Pubmed
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
  • Le Grand B, Panissie A, Perez M, Pauwels PJ, John GW: Zolmitriptan stimulates a Ca(2+)-dependent K(+) current in C6 glioma cells stably expressing recombinant human 5-HT(1B) receptors. Eur J Pharmacol. 2000 Jun 2;397(2-3):297-302. - Pubmed
  • Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10. - Pubmed
  • de Almeida RM, Nikulina EM, Faccidomo S, Fish EW, Miczek KA: Zolmitriptan--a 5-HT1B/D agonist, alcohol, and aggression in mice. Psychopharmacology (Berl). 2001 Sep;157(2):131-41. - Pubmed
  • Reuter U, Salomone S, Ickenstein GW, Waeber C: Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia. 2004 May;24(5):398-407. - Pubmed
  • Gowin JL, Swann AC, Moeller FG, Lane SD: Zolmitriptan and human aggression: interaction with alcohol. Psychopharmacology (Berl). 2010 Jul;210(4):521-31. Epub 2010 Apr 21. - Pubmed
  • Pascual J: [Mechanism of action of zolmitriptan] Neurologia. 1998 Oct;13 Suppl 2:9-15. - Pubmed
  • Martin GR: Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 Oct;17 Suppl 18:4-14. - Pubmed
DTHybrid score 0.4384
5-hydroxytryptamine 1F receptor
Name 5-hydroxytryptamine 1F receptor
Gene Name HTR1F
Pharmacological action yes
Actions agonist
References
  • Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. - Pubmed
  • Reuter U, Salomone S, Ickenstein GW, Waeber C: Effects of chronic sumatriptan and zolmitriptan treatment on 5-HT receptor expression and function in rats. Cephalalgia. 2004 May;24(5):398-407. - Pubmed
  • Villalon CM, Centurion D, Valdivia LF, de Vries P, Saxena PR: Migraine: pathophysiology, pharmacology, treatment and future trends. Curr Vasc Pharmacol. 2003 Mar;1(1):71-84. - Pubmed
  • Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR: An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. - Pubmed
  • Bhalla P, Sharma HS, Wurch T, Pauwels PJ, Saxena PR: Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht(1F) receptor. Eur J Pharmacol. 2002 Feb 1;436(1-2):23-33. - Pubmed
  • Wainscott DB, Johnson KW, Phebus LA, Schaus JM, Nelson DL: Human 5-HT1F receptor-stimulated [35S]GTPgammaS binding: correlation with inhibition of guinea pig dural plasma protein extravasation. Eur J Pharmacol. 1998 Jul 3;352(1):117-24. - Pubmed
DTHybrid score 0.414
5-hydroxytryptamine 1A receptor
Name 5-hydroxytryptamine 1A receptor
Gene Name HTR1A
Pharmacological action yes
Actions agonist
References
  • Johnson DE, Rollema H, Schmidt AW, McHarg AD: Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol. 2001 Aug 17;425(3):203-10. - Pubmed
DTHybrid score 0.4074

Enzymes


Cytochrome P450 1A2
Name Cytochrome P450 1A2
Gene Name CYP1A2
Actions substrate
References
  • Flockhart DA. - Drug Interactions: Cytochrome P450 Drug Interaction Table
  • Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. - Pubmed
DTHybrid score 0.3577
Amine oxidase [flavin-containing] A
Name Amine oxidase [flavin-containing] A
Gene Name MAOA
Actions substrate
References
  • Rolan P: Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia. 1997 Oct;17 Suppl 18:21-7. - Pubmed
  • Wild MJ, McKillop D, Butters CJ: Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica. 1999 Aug;29(8):847-57. - Pubmed
DTHybrid score 0.5788

Predictions


Id Partner name Gene Name Score
3939 Amine oxidase [flavin-containing] B MAOB 0.1756
4512 Cytochrome P450 3A4 CYP3A4 0.1644
4119 Cytochrome P450 2D6 CYP2D6 0.1607
502 5-hydroxytryptamine 2A receptor HTR2A 0.1347
318 Alpha-2A adrenergic receptor ADRA2A 0.1342
831 D(2) dopamine receptor DRD2 0.1187
1588 Multidrug resistance protein 1 ABCB1 0.1077
629 Alpha-2B adrenergic receptor ADRA2B 0.1071
436 5-hydroxytryptamine 2B receptor HTR2B 0.1062
590 5-hydroxytryptamine 2C receptor HTR2C 0.1032
23 D(1A) dopamine receptor DRD1 0.1026
378 Alpha-2C adrenergic receptor ADRA2C 0.1014
638 D(3) dopamine receptor DRD3 0.0977
6016 Cytochrome P450 2C19 CYP2C19 0.0926
432 D(4) dopamine receptor DRD4 0.0896
4757 Cytochrome P450 2C9 CYP2C9 0.0837
556 Alpha-1A adrenergic receptor ADRA1A 0.0831
163 D(1B) dopamine receptor DRD5 0.0764
716 5-hydroxytryptamine 7 receptor HTR7 0.0762
632 Alpha-1B adrenergic receptor ADRA1B 0.0645
193 Beta-1 adrenergic receptor ADRB1 0.063
6013 Cytochrome P450 2E1 CYP2E1 0.0562
766 Beta-2 adrenergic receptor ADRB2 0.0551
4118 Cytochrome P450 3A5 CYP3A5 0.055
824 Sodium-dependent serotonin transporter SLC6A4 0.055
528 5-hydroxytryptamine 1E receptor HTR1E 0.0531
6024 Cytochrome P450 1A1 CYP1A1 0.0457
6107 Cytochrome P450 3A7 CYP3A7 0.0456
5718 Cytochrome P450 2A6 CYP2A6 0.042
492 Histamine H1 receptor HRH1 0.042
4924 Cytochrome P450 2C8 CYP2C8 0.042
1732 ATP-binding cassette sub-family G member 2 ABCG2 0.041
713 Sodium-dependent dopamine transporter SLC6A3 0.0405
540 Sodium-dependent noradrenaline transporter SLC6A2 0.0403
789 Alpha-1D adrenergic receptor ADRA1D 0.037
1490 Solute carrier organic anion transporter family member 1B1 SLCO1B1 0.0362
6139 Solute carrier organic anion transporter family member 1A2 SLCO1A2 0.0335
6030 Cytochrome P450 2B6 CYP2B6 0.0334
341 5-hydroxytryptamine 3 receptor HTR3A 0.0311
1181 Alpha-1-acid glycoprotein 1 ORM1 0.0302
1256 5-hydroxytryptamine 6 receptor HTR6 0.0301
1517 Beta-3 adrenergic receptor ADRB3 0.0296
20 Prostaglandin G/H synthase 1 PTGS1 0.0291
103 Muscarinic acetylcholine receptor M1 CHRM1 0.0289
6145 Solute carrier family 22 member 1 SLC22A1 0.0265
36 Insulin receptor INSR 0.0258
587 Serum albumin ALB 0.0257
6101 Dimethylaniline monooxygenase [N-oxide-forming] 3 FMO3 0.0252
274 Muscarinic acetylcholine receptor M5 CHRM5 0.0247
450 Muscarinic acetylcholine receptor M4 CHRM4 0.024
94 5-hydroxytryptamine 4 receptor HTR4 0.0233
51 Muscarinic acetylcholine receptor M3 CHRM3 0.0215
617 Muscarinic acetylcholine receptor M2 CHRM2 0.021
6144 Solute carrier family 22 member 2 SLC22A2 0.0187
734 D1 dopamine receptor-interacting protein calcyon CALY 0.018
131 Synaptic vesicular amine transporter SLC18A2 0.0179
3811 Cytochrome P450 19A1 CYP19A1 0.0174
3810 Catechol O-methyltransferase COMT 0.0154
6106 Cytochrome P450 2C18 CYP2C18 0.013
1898 Cytochrome P450 1B1 CYP1B1 0.0127
477 DNA topoisomerase 4 subunit A parC 0.0127
886 DNA topoisomerase 4 subunit A parC 0.0127
6226 DNA topoisomerase 4 subunit A parC 0.0127
404 DNA gyrase subunit A gyrA 0.0125
6224 DNA gyrase subunit A gyrA 0.0125
1729 Solute carrier family 22 member 6 SLC22A6 0.0119
118 Organic cation/carnitine transporter 2 SLC22A5 0.0117
5698 Riboflavin synthase alpha chain ribE 0.0105
408 Riboflavin kinase RFK 0.0101
6147 Solute carrier family 22 member 3 SLC22A3 0.0098
146 Androgen receptor AR 0.0098
958 Insulin-like growth factor 1 receptor IGF1R 0.0097
817 DNA topoisomerase 2-alpha TOP2A 0.0096
1757 Myeloperoxidase MPO 0.0093
6025 UDP-glucuronosyltransferase 1-4 UGT1A4 0.0092
220 Sodium channel protein type 5 subunit alpha SCN5A 0.0091
290 Prostaglandin G/H synthase 2 PTGS2 0.009
485 cGMP-inhibited 3',5'-cyclic phosphodiesterase A PDE3A 0.0083
1656 CYP2B protein CYP2B 0.0081
3917 Methylenetetrahydrofolate reductase MTHFR 0.0075
654 Flavin reductase BLVRB 0.0075
1632 Solute carrier organic anion transporter family member 2B1 SLCO2B1 0.007
6014 Cytochrome P450 2A13 CYP2A13 0.007
847 Mu-type opioid receptor OPRM1 0.0066
6022 UDP-glucuronosyltransferase 1-1 UGT1A1 0.0066
1735 Canalicular multispecific organic anion transporter 1 ABCC2 0.0066
16 Adenosine A1 receptor ADORA1 0.0066
124 Histamine H2 receptor HRH2 0.0065
833 Organic cation/carnitine transporter 1 SLC22A4 0.0063
6017 Cholesterol side-chain cleavage enzyme, mitochondrial CYP11A1 0.0062
198 Sodium channel protein type 10 subunit alpha SCN10A 0.006
3923 Cholinesterase BCHE 0.0058
6031 Cytochrome P450 3A43 CYP3A43 0.0057
862 Multidrug resistance-associated protein 1 ABCC1 0.0055
1178 Adenosine A2a receptor ADORA2A 0.0053
6143 Solute carrier family 22 member 7 SLC22A7 0.0052
571 Melatonin receptor type 1A MTNR1A 0.0052
362 Melatonin receptor type 1B MTNR1B 0.0052
164 Histamine H4 receptor HRH4 0.0051
136 Estrogen receptor ESR1 0.0049
714 Glutathione reductase, mitochondrial GSR 0.0047
474 Acetylcholinesterase ACHE 0.0046
6164 POU domain, class 5, transcription factor 1 POU5F1 0.0046
6018 UDP-glucuronosyltransferase 1-9 UGT1A9 0.0045
465 Calmodulin CALM1 0.0045
6220 Aryl hydrocarbon receptor AHR 0.0045
101 Potassium voltage-gated channel subfamily H member 2 KCNH2 0.0044
776 Bile salt export pump ABCB11 0.0044
777 Tumor necrosis factor TNF 0.0044
6142 Solute carrier family 22 member 8 SLC22A8 0.0042
3913 Glutamic acid decarboxylase GAD65 0.0042
1636 Trace amine-associated receptor 1 TAAR1 0.0041
4115 Voltage-dependent L-type calcium channel subunit alpha-1D CACNA1D 0.0041
4111 Voltage-dependent L-type calcium channel subunit alpha-1S CACNA1S 0.004
964 Voltage-dependent T-type calcium channel subunit alpha-1H CACNA1H 0.004
478 Voltage-dependent L-type calcium channel subunit alpha-1C CACNA1C 0.004
385 Potassium-transporting ATPase alpha chain 1 ATP4A 0.0039
1483 Membrane copper amine oxidase AOC3 0.0039
605 Fumarate reductase flavoprotein subunit frdA 0.0038
2709 Fumarate reductase flavoprotein subunit SO_0970 0.0038
3673 Fumarate reductase flavoprotein subunit fccA 0.0038
4912 Fumarate reductase flavoprotein subunit ifcA 0.0038
6549 Fumarate reductase flavoprotein subunit frdA 0.0038
3947 Xanthine dehydrogenase/oxidase XDH 0.0038
6176 UDP-glucuronosyltransferase 1-3 UGT1A3 0.0037
15 Voltage-dependent T-type calcium channel subunit alpha-1I CACNA1I 0.0035
243 Ribosyldihydronicotinamide dehydrogenase [quinone] NQO2 0.0035
5998 Toll-like receptor 8 TLR8 0.0035
273 Apoptosis regulator Bcl-2 BCL2 0.0034
565 Extracellular calcium-sensing receptor CASR 0.0034
712 Tubulin alpha chain TUB1 0.0034
161 Tubulin beta chain TUBB 0.0034
312 Tubulin beta chain TUB2 0.0034
735 Alanine aminotransferase 1 GPT 0.0034
3904 Alanine aminotransferase 2 GPT2 0.0034
535 Voltage-dependent T-type calcium channel subunit alpha-1G CACNA1G 0.0034
541 cAMP-specific 3',5'-cyclic phosphodiesterase 4B PDE4B 0.0033
4122 Histone deacetylase 2 HDAC2 0.0033
468 Cytochrome P450 4A11 CYP4A11 0.0033
613 Atrial natriuretic peptide receptor A NPR1 0.0033
280 4-aminobutyrate aminotransferase, mitochondrial ABAT 0.0032
872 Gamma-aminobutyric-acid receptor subunit alpha-1 GABRA1 0.0031
2164 Multidrug resistance-associated protein 4 ABCC4 0.0031
6020 Aldehyde oxidase AOX1 0.0031
4095 Neuronal acetylcholine receptor subunit alpha-7 CHRNA7 0.0031
947 Neuronal acetylcholine receptor subunit alpha-4 CHRNA4 0.0031
6178 UDP-glucuronosyltransferase 2B7 UGT2B7 0.0031
818 50S ribosomal protein L10 rplJ 0.003
259 Microsomal triglyceride transfer protein large subunit MTTP 0.003
153 Dopamine beta-hydroxylase DBH 0.003
173 Toll-like receptor 7 TLR7 0.003
117 Sterol O-acyltransferase 1 SOAT1 0.003
580 Gamma-aminobutyric-acid receptor subunit alpha-3 GABRA3 0.0029
423 Gamma-aminobutyric-acid receptor subunit alpha-2 GABRA2 0.0029
1709 Canalicular multispecific organic anion transporter 2 ABCC3 0.0029
992 Protein tyrosine kinase 2 beta PTK2B 0.0028
147 Aldehyde dehydrogenase, mitochondrial ALDH2 0.0028
4110 Voltage-dependent L-type calcium channel subunit beta-2 CACNB2 0.0028
787 Vitamin K epoxide reductase complex subunit 1 VKORC1 0.0028
6044 Serum paraoxonase/lactonase 3 PON3 0.0028
756 Sex hormone-binding globulin SHBG 0.0027
1971 cAMP-specific 3',5'-cyclic phosphodiesterase 4A PDE4A 0.0027
3849 Insulin-like growth factor-binding protein 7 IGFBP7 0.0027
2009 Protein NOV homolog NOV 0.0027
3847 Neuroendocrine convertase 2 PCSK2 0.0027
1949 Carboxypeptidase E CPE 0.0027
3850 Synaptotagmin-like protein 4 SYTL4 0.0027
3848 Neuroendocrine convertase 1 PCSK1 0.0027
3846 Retinoblastoma-associated protein RB1 0.0027
6032 PROBABLE FATTY ACID SYNTHASE FAS (FATTY ACID SYNTHETASE) fas 0.0026
790 DNA polymerase subunit alpha B POLA2 0.0026
6079 Neuronal acetylcholine receptor subunit alpha-3 CHRNA3 0.0026
5880 Thrombopoietin receptor MPL 0.0025
6082 Neuronal acetylcholine receptor subunit beta-3 CHRNB3 0.0024
6080 Neuronal acetylcholine receptor subunit alpha-5 CHRNA5 0.0024
948 Neuronal acetylcholine receptor subunit beta-2 CHRNB2 0.0024
6070 Nischarin NISCH 0.0024
3804 Sodium channel protein type 4 subunit alpha SCN4A 0.0024
458 Neuronal acetylcholine receptor subunit alpha-10 CHRNA10 0.0023
523 Gamma-aminobutyric-acid receptor subunit alpha-5 GABRA5 0.0023
550 Amiloride-sensitive sodium channel subunit delta SCNN1D 0.0023
27 Amiloride-sensitive sodium channel subunit beta SCNN1B 0.0023
552 Amiloride-sensitive sodium channel subunit gamma SCNN1G 0.0023
213 Amiloride-sensitive sodium channel subunit alpha SCNN1A 0.0023
3957 Adenosine deaminase ADA 0.0023
6148 Multidrug resistance-associated protein 7 ABCC10 0.0023
841 Gamma-aminobutyric-acid receptor subunit alpha-6 GABRA6 0.0023
858 Potassium voltage-gated channel subfamily A member 1 KCNA1 0.0023
530 Gamma-aminobutyric-acid receptor subunit alpha-4 GABRA4 0.0023
762 Voltage-dependent calcium channel subunit alpha-2/delta-1 CACNA2D1 0.0022
4113 Voltage-dependent L-type calcium channel subunit alpha-1F CACNA1F 0.0022
6068 Guanylate cyclase soluble subunit alpha-2 GUCY1A2 0.0022
4097 Neuronal acetylcholine receptor subunit alpha-9 CHRNA9 0.0022
6081 Neuronal acetylcholine receptor subunit alpha-6 CHRNA6 0.0022
26 Vascular endothelial growth factor receptor 3 FLT4 0.0022
2155 Insulin-degrading enzyme IDE 0.0022
731 HIV-1 protease HIV-1 protease 0.0021
1638 Solute carrier family 2, facilitated glucose transporter member 2 SLC2A2 0.0021
1284 Nuclear receptor subfamily 1 group I member 2 NR1I2 0.0021
3802 Sodium channel protein type 2 subunit alpha SCN2A 0.0021
260 Cytochrome P450 51 ERG11 0.0021
761 Cytochrome P450 51 ERG11 0.0021
3163 Cytochrome P450 51 cyp51 0.0021
1995 Sodium channel protein type 9 subunit alpha SCN9A 0.0021
1244 Low-density lipoprotein receptor-related protein 2 LRP2 0.0021
1618 High affinity nerve growth factor receptor NTRK1 0.0021
32 Vascular endothelial growth factor receptor 1 FLT1 0.0021
869 Estrogen receptor beta ESR2 0.0021
6141 Sodium/bile acid cotransporter SLC10A1 0.0021
696 Kappa-type opioid receptor OPRK1 0.0021
871 Glucocorticoid receptor NR3C1 0.0021
6100 BDNF/NT-3 growth factors receptor NTRK2 0.0021
6206 DNA-directed RNA polymerase subunit beta' rpoC 0.002
6078 Neuronal acetylcholine receptor subunit beta-4 CHRNB4 0.002
6133 Sodium channel subunit beta-2 SCN2B 0.002
6134 Sodium channel subunit beta-3 SCN3B 0.002
6132 Sodium channel subunit beta-1 SCN1B 0.002
6135 Sodium channel subunit beta-4 SCN4B 0.002
6127 Carbonic anhydrase-related protein CA8 0.002
6129 Carbonic anhydrase-related protein 11 CA11 0.002
6128 Carbonic anhydrase-related protein 10 CA10 0.002
1820 Beta-nerve growth factor NGF 0.002
4228 Keratin, type II cytoskeletal 7 KRT7 0.002
6104 Dimethylaniline monooxygenase [N-oxide-forming] 1 FMO1 0.002
228 Beta platelet-derived growth factor receptor PDGFRB 0.0019
6157 Solute carrier organic anion transporter family member 1B3 SLCO1B3 0.0019
73 Prostaglandin E2 receptor, EP1 subtype PTGER1 0.0019
6098 Potassium voltage-gated channel subfamily D member 2 KCND2 0.0019
6099 Potassium voltage-gated channel subfamily D member 3 KCND3 0.0019
1086 Potassium voltage-gated channel subfamily KQT member 2 KCNQ2 0.0019
284 DNA-directed RNA polymerase beta chain rpoB 0.0019
5773 DNA-directed RNA polymerase beta chain rpoB 0.0019
467 Delta-type opioid receptor OPRD1 0.0019
805 Cytochrome P450 11B1, mitochondrial CYP11B1 0.0019
512 DNA-directed RNA polymerase alpha chain rpoA 0.0019
5772 DNA-directed RNA polymerase alpha chain rpoA 0.0019
122 P2Y purinoceptor 12 P2RY12 0.0018
3803 Sodium channel protein type 3 subunit alpha SCN3A 0.0018
33 Cystine/glutamate transporter SLC7A11 0.0018
6130 Carbonic anhydrase 13 CA13 0.0018
6766 O-GlcNAcase BT_4395 BT_4395 0.0018
504 Mast/stem cell growth factor receptor KIT 0.0018
6124 Carbonic anhydrase 5B, mitochondrial CA5B 0.0018
1648 Elastin ELN 0.0017
215 Sodium channel protein type 11 subunit alpha SCN11A 0.0017
6040 6-phosphogluconate dehydrogenase, decarboxylating PGD 0.0017
275 Arachidonate 5-lipoxygenase ALOX5 0.0017
918 Glutamate receptor, ionotropic kainate 2 GRIK2 0.0017
407 Vascular endothelial growth factor receptor 2 KDR 0.0017
6131 Carbonic anhydrase 14 CA14 0.0017
1830 5'-nucleotidase NT5E 0.0016
390 Adenosine A3 receptor ADORA3 0.0016
204 cGMP-specific 3',5'-cyclic phosphodiesterase PDE5A 0.0016
1243 Cathepsin D CTSD 0.0016
1010 Cytochrome P450 51A1 CYP51A1 0.0016
373 Transthyretin TTR 0.0016
610 Calcium-activated potassium channel subunit alpha 1 KCNMA1 0.0016
427 Substance-P receptor TACR1 0.0016
6122 Carbonic anhydrase 3 CA3 0.0016
698 B-Raf proto-oncogene serine/threonine-protein kinase BRAF 0.0016
921 Glutamate receptor 2 GRIA2 0.0015
6045 Voltage-dependent calcium channel subunit alpha-2/delta-3 CACNA2D3 0.0015
462 Intermediate conductance calcium-activated potassium channel protein 4 KCNN4 0.0015
6123 Carbonic anhydrase 5A, mitochondrial CA5A 0.0015
6177 UDP-glucuronosyltransferase 1-10 UGT1A10 0.0015
70 Type-1 angiotensin II receptor AGTR1 0.0015
2499 Tubulin beta-2C chain TUBB2C 0.0015
3844 HLA class II histocompatibility antigen, DQ(6) alpha chain HLA-DQA2 0.0015
6432 Transporter snf 0.0015
3007 Carbonic anhydrase 12 CA12 0.0014
4205 Carbonic anhydrase 9 CA9 0.0014
813 Neuronal acetylcholine receptor subunit alpha-2 CHRNA2 0.0014
295 Carbonic anhydrase 1 CA1 0.0014
6102 Arylamine N-acetyltransferase 2 NAT2 0.0014
620 Bifunctional dihydrofolate reductase-thymidylate synthase Not Available 0.0014
2091 Endoplasmin HSP90B1 0.0014
6859 Protein S100-A4 S100A4 0.0014
904 Glutathione S-transferase P GSTP1 0.0014
2449 Tubulin alpha-3 chain TUBA1A 0.0014
6126 Carbonic anhydrase 7 CA7 0.0013
80 Peroxisome proliferator-activated receptor alpha PPARA 0.0013
158 Sodium channel protein type 1 subunit alpha SCN1A 0.0013
543 Penicillin-binding protein 1B mrcB 0.0013
6186 Penicillin-binding protein 1B ponB 0.0013
6822 Penicillin-binding protein 1b pbp1b 0.0013
6844 Penicillin-binding protein 1b pbp1b 0.0013
2157 NAD(P)H dehydrogenase [quinone] 1 NQO1 0.0013
380 Cytochrome P450 17A1 CYP17A1 0.0013
844 Epidermal growth factor receptor EGFR 0.0013
645 Penicillin-binding protein 1A mrcA 0.0013
5805 Penicillin-binding protein 1A ponA 0.0013
6185 Penicillin-binding protein 1A mrcA 0.0013
6799 Penicillin-binding protein 1A pbpA 0.0013
159 Penicillin-binding protein 2B penA 0.0013
6121 Penicillin-binding protein 2B penA 0.0013
5626 Nucleoside diphosphate kinase B NME2 0.0013
424 Dihydroorotate dehydrogenase, mitochondrial DHODH 0.0013
1024 Solute carrier family 22 member 11 SLC22A11 0.0013
6146 High affinity copper uptake protein 1 SLC31A1 0.0012
4311 tRNA TRDMT1 0.0012
4325 tRNA trmD 0.0012
4328 tRNA trmD 0.0012
6158 Solute carrier organic anion transporter family member 1C1 SLCO1C1 0.0012
518 Peroxidase/catalase T katG 0.0012
1629 Transcription factor AP-1 JUN 0.0012
1787 Nuclear factor NF-kappa-B p105 subunit NFKB1 0.0012
482 Glycine receptor subunit alpha-1 GLRA1 0.0011
828 Phenylalanine-4-hydroxylase PAH 0.0011
3109 Phenylalanine-4-hydroxylase phhA 0.0011
4238 50S ribosomal protein L4 rplD 0.0011
5578 50S ribosomal protein L4 rplD 0.0011
6173 50S ribosomal protein L4 rplD 0.0011
6219 50S ribosomal protein L4 rplD 0.0011
6043 Putative G-protein coupled receptor 44 GPR44 0.0011
563 Thyroid peroxidase TPO 0.0011
4192 DNA topoisomerase 2-beta TOP2B 0.0011
592 Carbonic anhydrase 4 CA4 0.0011
950 Alpha platelet-derived growth factor receptor PDGFRA 0.001
634 Squalene monooxygenase SQLE 0.001
7196 Squalene monooxygenase ERG1 0.001
239 Coagulation factor X F10 0.001
4237 50S ribosomal protein L22 rplV 0.001
6136 Multidrug resistance-associated protein 5 ABCC5 0.001
1714 Mitogen-activated protein kinase 3 MAPK3 0.001
1302 Dihydropyrimidine dehydrogenase [NADP+] DPYD 0.001
4604 Liver carboxylesterase 1 CES1 0.001
564 Cellular retinoic acid-binding protein 1 CRABP1 0.001
5294 Nucleoside diphosphate kinase A NME1 0.001
908 Glutathione S-transferase theta-1 GSTT1 0.001
1192 Sulfotransferase 1A1 SULT1A1 0.001
4120 NADPH--cytochrome P450 reductase POR 0.001
706 Glutamate [NMDA] receptor subunit 3A GRIN3A 0.001
6153 Solute carrier organic anion transporter family member 4A1 SLCO4A1 0.001
778 Cysteinyl leukotriene receptor 1 CYSLTR1 0.001
859 Cellular retinoic acid-binding protein 2 CRABP2 0.001
522 26S proteasome non-ATPase regulatory subunit 2 PSMD2 0.001
515 26S proteasome non-ATPase regulatory subunit 1 PSMD1 0.001
1457 Long-chain-fatty-acid--CoA ligase 4 ACSL4 0.001
823 Fibroblast growth factor receptor 2 FGFR2 0.001
1561 Troponin C, slow skeletal and cardiac muscles TNNC1 0.001
1939 Heat shock protein HSP 90-alpha HSP90AA1 0.001
6137 Multidrug resistance-associated protein 6 ABCC6 0.0009
6182 Cytochrome P450 2J2 CYP2J2 0.0009
780 Retinoic acid receptor RXR-gamma RXRG 0.0009
229 Retinoic acid receptor beta RARB 0.0009
730 Retinoic acid receptor alpha RARA 0.0009
4100 Gamma-aminobutyric-acid receptor subunit beta-2 GABRB2 0.0009
6179 UDP-glucuronosyltransferase 2B17 UGT2B17 0.0009
365 Dihydrofolate reductase DHFR 0.0009
2381 Dihydrofolate reductase DFR1 0.0009
2833 Dihydrofolate reductase Not Available 0.0009
2931 Dihydrofolate reductase folA 0.0009
3544 Dihydrofolate reductase folA 0.0009
3682 Dihydrofolate reductase folA 0.0009
6642 Dihydrofolate reductase folA 0.0009
6756 Dihydrofolate reductase dfrA 0.0009
4439 Ferredoxin reductase bphA4 0.0009
4486 Phenol 2-hydroxylase component B pheA2 0.0009
4477 Dihydrolipoyl dehydrogenase lpdV 0.0009
5077 Dihydrolipoyl dehydrogenase Not Available 0.0009
5117 Dihydrolipoyl dehydrogenase lpd 0.0009
4099 Gamma-aminobutyric-acid receptor subunit beta-3 GABRB3 0.0009
1502 Peroxisome proliferator-activated receptor delta PPARD 0.0009
5078 Amine oxidase, flavin-containing PSPTO1126 0.0009
5095 Putidaredoxin reductase camA 0.0009
5122 Mersacidin decarboxylase mrsD 0.0009
526 Thioredoxin reductase trxB 0.0009
3767 Thioredoxin reductase trxB 0.0009
5114 Putative acyl-CoA dehydrogenase TT_C0779 0.0009
5107 Alkyl hydroperoxide reductase subunit F ahpF 0.0009
5118 Alkyl hydroperoxide reductase subunit F ahpF 0.0009
5109 Outer membrane protein p64k or PM-6 m-6 0.0009
5097 PROBABLE DIHYDROLIPOAMIDE DEHYDROGENASE LPDA lpdA 0.0009
5115 FkbI fkbI 0.0009
3133 UDP-galactopyranose mutase glf 0.0009
5099 UDP-galactopyranose mutase glf 0.0009
1329 Apoptosis-inducing factor 1, mitochondrial AIFM1 0.0009
5083 Cryptochrome DASH cry 0.0009
5100 Gamma-aminobutyrate metabolism dehydratase/isomerase abfD 0.0009
5102 4-cresol dehydrogenase [hydroxylating] flavoprotein subunit pchF 0.0009
3763 5,10-methylenetetrahydrofolate reductase metF 0.0009
3918 5,10-methylenetetrahydrofolate reductase MTHFR 0.0009
5094 5,10-methylenetetrahydrofolate reductase metF 0.0009
5081 L-aspartate oxidase nadB 0.0009
5111 Phenylacetone monooxygenase pamO 0.0009
1410 Oxidoreductase HSD17B6 0.0008
4725 Oxidoreductase Not Available 0.0008
5124 Oxidoreductase Not Available 0.0008
5112 Benzoate 1,2-dioxygenase electron transfer component benC 0.0008
459 Retinoic acid receptor RXR-alpha RXRA 0.0008
88 Retinoic acid receptor RXR-beta RXRB 0.0008
2236 Casein kinase II subunit alpha CSNK2A1 0.0008
357 Carbonic anhydrase 2 CA2 0.0008
3830 Calreticulin CALR 0.0008
162 Retinoic acid receptor gamma-1 RARG 0.0008
6167 Organic solute transporter subunit beta OSTB 0.0008
6166 Organic solute transporter subunit alpha OSTA 0.0008
6181 UDP-glucuronosyltransferase 1-8 UGT1A8 0.0008
17 Proto-oncogene tyrosine-protein kinase ABL1 ABL1 0.0008
368 Enoyl-[acyl-carrier-protein] reductase [NADH] inhA 0.0008
3228 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0008
3678 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0008
6856 Enoyl-[acyl-carrier-protein] reductase [NADH] fabI 0.0008
4114 Voltage-dependent L-type calcium channel subunit beta-3 CACNB3 0.0008
4112 Voltage-dependent L-type calcium channel subunit beta-4 CACNB4 0.0008
6034 Hydroxyindole O-methyltransferase ASMT 0.0008
6035 Nuclear receptor ROR-beta RORB 0.0008
6036 Eosinophil peroxidase EPX 0.0008
811 Translocator protein TSPO 0.0008
3856 Fibroblast growth factor receptor 3 FGFR3 0.0008
4440 NADH peroxidase npr 0.0008
3102 Flavohemoprotein hmp 0.0008
4969 Flavohemoprotein hmp 0.0008
976 Platelet glycoprotein IX GP9 0.0008
1374 Natriuretic peptides B NPPB 0.0008
1827 Gap junction alpha-1 protein GJA1 0.0008
1908 Vascular cell adhesion protein 1 VCAM1 0.0008
400 Coagulation factor IX F9 0.0008
5461 Coagulation factor IX F9 0.0008
327 Glutathione reductase gor 0.0007
5110 Glutathione reductase GR2 0.0007
5091 UDP-N-acetylenolpyruvoylglucosamine reductase murB 0.0007
5093 UDP-N-acetylenolpyruvoylglucosamine reductase murB 0.0007
4103 Proteasome subunit beta type 2 PSMB2 0.0007
4102 Proteasome subunit beta type 5 PSMB5 0.0007
3594 Deoxyribodipyrimidine photo-lyase phr 0.0007
5079 Deoxyribodipyrimidine photo-lyase phrB 0.0007
5080 Deoxyribodipyrimidine photo-lyase phr 0.0007
4101 Proteasome subunit beta type 1 PSMB1 0.0007
1063 Signal transducer and activator of transcription 5B STAT5B 0.0007
935 Proto-oncogene tyrosine-protein kinase Yes YES1 0.0007
5072 N,N-dimethylglycine oxidase dmg 0.0007
178 NADH-cytochrome b5 reductase 3 CYB5R3 0.0007
812 Dihydrolipoyl dehydrogenase, mitochondrial DLD 0.0007
4226 Uridine phosphorylase 2 UPP2 0.0007
2470 Pyruvate oxidase pox5 0.0007
5073 Ferredoxin--NADP reductase petH 0.0007
5076 Ferredoxin--NADP reductase fpr 0.0007
5119 Ferredoxin--NADP reductase petH 0.0007
5121 Ferredoxin--NADP reductase fpr 0.0007
5075 Sulfite reductase [NADPH] flavoprotein alpha-component cysJ 0.0007
440 Isovaleryl-CoA dehydrogenase, mitochondrial IVD 0.0007
3506 Glutaryl-CoA dehydrogenase, mitochondrial GCDH 0.0007
667 Acyl-CoA dehydrogenase family member 8, mitochondrial ACAD8 0.0007
5003 Acyl-CoA dehydrogenase, short-chain specific Not Available 0.0007
2268 Cholesterol oxidase choB 0.0007
2822 Cholesterol oxidase choA 0.0007
2526 NADPH-ferredoxin reductase fprA fprA 0.0007
6639 Peroxisomal acyl-coenzyme A oxidase 1 ACOX1 0.0007
3247 2-oxopropyl-CoM reductase, carboxylating xecC 0.0007
3970 Voltage-dependent N-type calcium channel subunit alpha-1B CACNA1B 0.0007
2450 Tyrosine-protein kinase ITK/TSK ITK 0.0007
814 Ryanodine receptor 1 RYR1 0.0007
822 Aldose reductase AKR1B1 0.0007
126 D-lactate dehydrogenase dld 0.0007
3545 D-lactate dehydrogenase Not Available 0.0007
4510 D-lactate dehydrogenase ldhA 0.0007
333 Voltage-dependent L-type calcium channel subunit beta-1 CACNB1 0.0007
6160 Solute carrier organic anion transporter family member 3A1 SLCO3A1 0.0007
4081 Vitamin K epoxide reductase complex subunit 1-like protein 1 VKORC1L1 0.0007
604 Vitamin K-dependent protein Z PROZ 0.0007
6228 Nuclear receptor coactivator 1 NCOA1 0.0007
6241 Nuclear receptor coactivator 2 NCOA2 0.0007
6046 Voltage-gated calcium channel beta 1 subunit splice variant CavB1d CACNB1 0.0007
765 Indoleamine 2,3-dioxygenase IDO1 0.0007
251 Alcohol dehydrogenase 1A ADH1A 0.0007
3185 Medium-chain specific acyl-CoA dehydrogenase, mitochondrial ACADM 0.0007
3254 Bifunctional protein putA [Includes: Proline dehydrogenase putA 0.0007
4160 Voltage-dependent calcium channel subunit alpha-2/delta-2 CACNA2D2 0.0007
4225 Uridine phosphorylase 1 UPP1 0.0007
2893 Glycine oxidase thiO 0.0007
705 Glutamate receptor 1 GRIA1 0.0007
241 Calcium-transporting ATPase type 2C member 1 ATP2C1 0.0007
934 Proto-oncogene tyrosine-protein kinase Fyn FYN 0.0006
839 Short-chain specific acyl-CoA dehydrogenase, mitochondrial ACADS 0.0006
2769 P-hydroxybenzoate hydroxylase pobA 0.0006
2809 P-hydroxybenzoate hydroxylase pobA 0.0006
3573 2,4-dienoyl-CoA reductase [NADPH] fadH 0.0006
194 NADH dehydrogenase [ubiquinone] 1 subunit C2 NDUFC2 0.0006
2567 Thymidylate synthase thyX thyX 0.0006
820 Glycine receptor subunit alpha-2 GLRA2 0.0006
2823 Trypanothione reductase TPR 0.0006
268 Adenosine A2b receptor ADORA2B 0.0006
1245 Vitamin K-dependent protein S PROS1 0.0006
413 Amidophosphoribosyltransferase PPAT 0.0006
2515 Amidophosphoribosyltransferase purF 0.0006
3714 Amidophosphoribosyltransferase purF 0.0006
422 Vitamin K-dependent protein C PROC 0.0006
537 ATP synthase delta chain, mitochondrial ATP5D 0.0006
936 Ephrin type-A receptor 2 EPHA2 0.0006
6091 Gamma-aminobutyric acid receptor subunit theta GABRQ 0.0006
238 Peroxisome proliferator-activated receptor gamma PPARG 0.0006
484 Tyrosine-protein kinase ABL2 ABL2 0.0006
559 NADH-ubiquinone oxidoreductase chain 1 MT-ND1 0.0006
444 Alcohol dehydrogenase 1B ADH1B 0.0006
6152 Solute carrier organic anion transporter family member 2A1 SLCO2A1 0.0006
6645 D-amino-acid oxidase DAO 0.0006
3610 Thioredoxin reductase 1, cytoplasmic TXNRD1 0.0006
464 Glutamate [NMDA] receptor subunit epsilon-2 GRIN2B 0.0006
2380 Monomeric sarcosine oxidase soxA 0.0006
5251 Carbonyl reductase [NADPH] 1 CBR1 0.0006
183 Vascular endothelial growth factor A VEGFA 0.0006
6163 Copper-transporting ATPase 2 ATP7B 0.0006
6165 Copper-transporting ATPase 1 ATP7A 0.0006
6086 Gamma-aminobutyric acid receptor subunit gamma-2 GABRG2 0.0006
448 Vitamin K-dependent gamma-carboxylase GGCX 0.0006
1864 RET proto-oncogene RET 0.0006
6090 Gamma-aminobutyric acid receptor subunit pi GABRP 0.0006
6092 Gamma-aminobutyric acid receptor subunit rho-2 GABRR2 0.0006
6088 Gamma-aminobutyric acid receptor subunit gamma-3 GABRG3 0.0006
6115 Gamma-aminobutyric acid receptor subunit rho-3 GABRR3 0.0006
1950 Epithelial discoidin domain-containing receptor 1 DDR1 0.0006
6094 BCR/ABL fusion protein isoform X9 BCR/ABL fusion 0.0006
6170 ATP-binding cassette sub-family A member 3 ABCA3 0.0006
6093 Gamma-aminobutyric acid receptor subunit delta GABRD 0.0006
6087 Gamma-aminobutyric acid receptor subunit gamma-1 GABRG1 0.0006
6089 Gamma-aminobutyric acid receptor subunit epsilon GABRE 0.0006
142 Gamma-aminobutyric-acid receptor subunit rho-1 GABRR1 0.0006
4098 Gamma-aminobutyric-acid receptor subunit beta-1 GABRB1 0.0005
1275 Estrogen sulfotransferase SULT1E1 0.0005
6933 Calcium-activated potassium channel subunit beta-4 KCNMB4 0.0005
6932 Calcium-activated potassium channel subunit beta-3 KCNMB3 0.0005
6931 Calcium-activated potassium channel subunit beta-1 KCNMB1 0.0005
6936 Small conductance calcium-activated potassium channel protein 3 KCNN3 0.0005
6934 Small conductance calcium-activated potassium channel protein 1 KCNN1 0.0005
6935 Small conductance calcium-activated potassium channel protein 2 KCNN2 0.0005
4152 Superoxide dismutase [Cu-Zn] SOD1 0.0005
3639 Thymidine phosphorylase deoA 0.0005
3936 Thymidine phosphorylase TYMP 0.0005
760 Fibroblast growth factor 1 FGF1 0.0005
517 Alcohol dehydrogenase 1C ADH1C 0.0005
798 Osteocalcin BGLAP 0.0005
5934 Cytochrome P450 26A1 CYP26A1 0.0005
1050 Bile salt sulfotransferase SULT2A1 0.0005
751 Potassium channel subfamily K member 6 KCNK6 0.0005
1039 Histone deacetylase 9 HDAC9 0.0005
1360 Sphingomyelin phosphodiesterase SMPD1 0.0005
631 3-hydroxy-3-methylglutaryl-coenzyme A reductase HMGCR 0.0005
3387 3-hydroxy-3-methylglutaryl-coenzyme A reductase mvaA 0.0005
937 Proto-oncogene tyrosine-protein kinase LCK LCK 0.0005
6002 Prostaglandin E2 receptor EP4 subtype PTGER4 0.0005
369 Coagulation factor VII F7 0.0005
896 Glutathione S-transferase Mu 1 GSTM1 0.0005
3937 Fatty-acid amide hydrolase FAAH 0.0005
2222 Equilibrative nucleoside transporter 1 SLC29A1 0.0005
5463 Calcium-activated potassium channel subunit beta 2 KCNMB2 0.0005
172 Potassium channel subfamily K member 1 KCNK1 0.0005
76 Nitric-oxide synthase, brain NOS1 0.0005
6023 Cytochrome P450 11B2, mitochondrial CYP11B2 0.0005
40 RAF proto-oncogene serine/threonine-protein kinase RAF1 0.0004
6149 Solute carrier family 22 member 10 SLC22A10 0.0004
165 FL cytokine receptor FLT3 0.0004
4131 Prostaglandin E2 receptor, EP3 subtype PTGER3 0.0004
951 Macrophage colony-stimulating factor 1 receptor CSF1R 0.0004
182 2-oxoglutarate dehydrogenase E1 component, mitochondrial OGDH 0.0004
406 Prostaglandin E2 receptor, EP2 subtype PTGER2 0.0004
630 Short/branched chain specific acyl-CoA dehydrogenase, mitochondrial ACADSB 0.0004
4177 Proto-oncogene tyrosine-protein kinase receptor ret RET 0.0004
24 Thymidylate synthase TMP1 0.0004
359 Thymidylate synthase TYMS 0.0004
2626 Thymidylate synthase thyA 0.0004
2729 Thymidylate synthase thyA 0.0004
5352 Thymidylate synthase THYA 0.0004
389 Amiloride-sensitive cation channel 2, neuronal ACCN2 0.0004
4162 Potassium voltage-gated channel subfamily KQT member 3 KCNQ3 0.0004
3854 Basic fibroblast growth factor receptor 1 FGFR1 0.0004
514 Potassium voltage-gated channel subfamily H member 6 KCNH6 0.0004
772 Potassium voltage-gated channel subfamily H member 7 KCNH7 0.0004
170 Succinate semialdehyde dehydrogenase, mitochondrial ALDH5A1 0.0004
933 Proto-oncogene tyrosine-protein kinase Src SRC 0.0004
737 Mineralocorticoid receptor NR3C2 0.0004
6155 ATP-binding cassette transporter sub-family C member 11 ABCC11 0.0004
6154 Multidrug and toxin extrusion protein 1 SLC47A1 0.0004
1539 Oligopeptide transporter, small intestine isoform SLC15A1 0.0004
614 Progesterone receptor PGR 0.0003
6085 Fatty acid-binding protein, intestinal FABP2 0.0003
2981 Phospholipase A2, membrane associated PLA2G2A 0.0003
54 Prothrombin F2 0.0003
738 Monocarboxylate transporter 1 SLC16A1 0.0003
7 Nitric oxide synthase, inducible NOS2 0.0003
392 Voltage-dependent P/Q-type calcium channel subunit alpha-1A CACNA1A 0.0003
291 Nitric-oxide synthase, endothelial NOS3 0.0003
781 ATP-sensitive inward rectifier potassium channel 11 KCNJ11 0.0002
↑